Results 61 to 70 of about 27,792 (251)

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin

Clinical Pharmacology &Therapeutics, EarlyView.
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul, Waseem Mujahed, Ibrahim Idries, Maor Wanounou, Meir Bialer, Yoseph Caraco   +5 more
wiley   +1 more source

Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis, 2011
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD).
Arash Akhlaghi, Shahin Shirani, Naghmeh Ziaie, Omid Pirhaji, Majid Yaran, Golnoosh Shahverdi, Nizal Sarrafzadegan, Alireza khosravi, Elham khosravi   +8 more
doaj  

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, EarlyView.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response

Indian Heart Journal, 2013
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug is implicated. In the present study, the prevalence of single nucleotide polymorphisms of MDR1 (C3435T), CYP2C19 [CYP2C19*2 CYP2C19*3, CYP2C19*17] and ...
Kavita K. Shalia, Vinod K. Shah, Poonam Pawar, Siddhi S. Divekar, Satchidanand Payannavar   +4 more
doaj   +1 more source

Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy [PDF]

Терапевтический архив, 2017
In current clinical practice, there is no optimal empirical therapy for Helicobacter pylori (H. pylori) infection and there is a progressive decrease in the efficiency of classical eradication therapy (ET) regimens.
I V Maev, D N Andreev
doaj   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype

Journal of Pharmacological Sciences, 2019
Polymorphisms of cytochrome P450 (CYP) enzymes can affect enzymatic activity, drug metabolism and drug interactions. Although the potential for drug interactions is especially important when co-administering drugs with strong inductive or inhibitory ...
Chiaki Kamiya, Naoki Inui, Akio Hakamata, Sachiko Miyakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Keiichi Odagiri, Hiroshi Watanabe   +8 more
doaj   +1 more source

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj  

A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel

Scientific Reports
CYP2C19 gene has multiple single nucleotide polymorphism (SNP), which is the major determinant for clopidogrel treatment responses. Therefore, CYP2C19 SNP detection is essential for predicting clopidogrel efficacy.
Hongwei Li, Yizhen Fang, Yongquan Chen, Yuning Lin, Zanxi Fang, Zhiyuan Lin, Huabin Xie, Zhongying Zhang   +7 more
doaj   +1 more source